Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 21.95% is 58% above its 5-year average of 13.86%, near the high end of its 5-year range (0.29%–21.95%).
As of the fiscal period ended Wednesday, December 31, 2025. 14.56% above its 12-month average of 19.16%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
21.95%
RETURN ON EQUITY (ROE) AVG TTM
19.16%
RETURN ON EQUITY (ROE) AVG 3Y
15.60%
RETURN ON EQUITY (ROE) AVG 5Y
13.86%
RETURN ON EQUITY (ROE) AVG 10Y
15.41%
RETURN ON EQUITY (ROE) AVG 15Y
16.52%
RETURN ON EQUITY (ROE) AVG 20Y
22.72%
CURRENT VS TTM AVG
+14.56%
CURRENT VS 3Y AVG
+40.68%
CURRENT VS 5Y AVG
+58.37%
CURRENT VS 10Y AVG
+42.44%
CURRENT VS 15Y AVG
+32.88%
CURRENT VS 20Y AVG
-3.39%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+101.56%
vs the sector median at left
AstraZeneca PLC
Market Cap
$131.47B
Return on Equity (ROE)
21.95%
TTM Avg
19.16%
3Y Avg
15.60%
5Y Avg
13.86%
Market Cap
$133.25B
Return on Equity (ROE)
3.79%
TTM Avg
4.23%
3Y Avg
6.35%
5Y Avg
7.74%
Market Cap
$133.37B
Return on Equity (ROE)
41.59%
TTM Avg
-8.30%
3Y Avg
7.76%
5Y Avg
4.45%
Market Cap
$137.13B
Return on Equity (ROE)
7.61%
TTM Avg
7.38%
3Y Avg
9.51%
5Y Avg
10.24%
Market Cap
$124.86B
Return on Equity (ROE)
7.78%
TTM Avg
14.50%
3Y Avg
15.05%
5Y Avg
14.30%
Market Cap
$124.82B
Return on Equity (ROE)
17.28%
TTM Avg
15.07%
3Y Avg
13.91%
5Y Avg
13.46%
Market Cap
$121.09B
Return on Equity (ROE)
22.41%
TTM Avg
8.96%
3Y Avg
15.60%
5Y Avg
19.47%
Market Cap
$142.54B
Return on Equity (ROE)
8.31%
TTM Avg
9.04%
3Y Avg
13.32%
5Y Avg
16.07%
Market Cap
$109.30B
Return on Equity (ROE)
9.70%
TTM Avg
9.71%
3Y Avg
8.51%
5Y Avg
8.44%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $131.47B | 21.95% | 19.16% | 15.60% | 13.86% |
| CVS Health Corp. (CVS)vs › | $133.25B | 3.79% | 4.23% | 6.35% | 7.74% |
| Bristol-Myers Squibb Company (BMY)vs › | $133.37B | 41.59% | -8.30% | 7.76% | 4.45% |
| Danaher Corporation (DHR)vs › | $137.13B | 7.61% | 7.38% | 9.51% | 10.24% |
| Stryker Corporation (SYK)vs › | $124.86B | 7.78% | 14.50% | 15.05% | 14.30% |
| Intuitive Surgical, Inc. (ISRG)vs › | $124.82B | 17.28% | 15.07% | 13.91% | 13.46% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $121.09B | 22.41% | 8.96% | 15.60% | 19.47% |
| Pfizer Inc. (PFE)vs › | $142.54B | 8.31% | 9.04% | 13.32% | 16.07% |
| Medtronic plc (MDT)vs › | $109.30B | 9.70% | 9.71% | 8.51% | 8.44% |
| GSK plc (GSK)vs › | $103.56B | 25.19% | 26.90% | 55.97% | 45.70% |
ROE
21.9%
ROA
9.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 21.07% |
| 2024-12-31 | 17.25% |
| 2023-12-31 | 15.21% |
| 2022-12-31 | 8.88% |
| 2021-12-31 | 0.29% |
| 2020-12-31 | 20.46% |
| 2019-12-31 | 10.17% |
| 2018-12-31 | 17.28% |
| 2017-12-31 | 20.06% |
| 2016-12-31 | 23.56% |
| 2015-12-31 | 15.28% |
| 2014-12-31 | 6.28% |
| 2013-12-31 | 11.01% |
| 2012-12-31 | 26.29% |
| 2011-12-31 | 42.66% |
| 2010-12-31 | 34.69% |
| 2009-12-31 | 36.40% |
| 2008-12-31 | 38.34% |
| 2007-12-31 | 37.86% |
| 2006-12-31 | 39.49% |
| 2005-12-31 | 34.61% |
| 2004-12-31 | 25.44% |
| 2003-12-31 | 23.04% |
| 2002-12-31 | 25.40% |
| 2001-12-31 | 30.31% |
| 2000-12-31 | 26.67% |
| 1999-12-31 | 11.09% |
| 1998-12-31 | 28.40% |
| 1997-12-31 | 33.80% |
| 1996-12-31 | 31.61% |
